Clinical Trial Update: Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pembrolizumab/vibostolimab with chemoradiotherapy followed by pembrolizumab/vibostolimab versus durvalumab in stage III non-small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Pembrolizumab (pembrolizumab)
• Vibostolimab (MK-7684A) (vibostolimab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED